Dexmedetomidine
Dexmedetomidine Hydrochloride
Also known as: Dexdomitor · Precedex · (S)-medetomidine · MPV 1440 · MPV 295 · MPV 785
Reviewed by the VetSheet Veterinary TeamUpdated Apr 5, 2026Evidence-based veterinary reference
Audited v13 dosing evidence
Reviewed non-calculator evidenceReviewed non-calculator evidence (2)
Evidence only — not for automatic calculation
Light sedation (often used for preanesthesia)
a) Light sedation (often used for preanesthesia): 5 – 15 µg/kg IV, IM, or SC
Governing clinical context (7)
- 1. Dexmedetomidine dosages depend on the combination of drugs used and the dosage(s) of the other drug(s). Premedication with dexmedetomidine will significantly reduce the dose of the induction agent required and will reduce volatile anesthetic requirements for maintenance anesthesia. All anesthetic agents used for induction or maintenance of anesthesia should be administered to effect.
- 2. Dose adjustments will also need to be made to account for the degree of desired sedation; type, duration, and pain level of the procedure; and patient temperament and body weight/size.
- 3. Dosing based on body surface area (BSA; or allometric scaling) is not common in clinical practice but decreases the variability in drug response between giant/large and small/toy breed dogs. See Conversion Tables: Body Weight (kg) to Body Surface Area (m 2 ).
- 4. For all dosages, the low end of the dose range is generally appropriate for IV administration, whereas the mid-upper range is most appropriate for IM or SC administration. Higher dosages will provide more profound sedation and analgesia.
- 5. When SC administration is used, the speed of sedation is slower, and the level of sedation is lighter and inconsistent. For more predictable sedation, IM or IV administration is recommended.
- 6. The effects of dexmedetomidine can be reversed with atipamezole. It is most often dosed by volume at ½ or the same volume of dexmedetomidine that was administered and given IM. See Atipamezole.
- Store the injection at room temperature (ie, 15°C-30°C [59°F-86°F]); do not freeze. Discard unused product 90 days after first piercing the vial.
Evidence only — not for automatic calculation
Deep sedation
c) Deep sedation: 40 µg/kg IV, IM, or SC
Governing clinical context (7)
- 1. Dexmedetomidine dosages depend on the combination of drugs used and the dosage(s) of the other drug(s). Premedication with dexmedetomidine will significantly reduce the dose of the induction agent required and will reduce volatile anesthetic requirements for maintenance anesthesia. All anesthetic agents used for induction or maintenance of anesthesia should be administered to effect.
- 2. Dose adjustments will also need to be made to account for the degree of desired sedation; type, duration, and pain level of the procedure; and patient temperament and body weight/size.
- 3. Dosing based on body surface area (BSA; or allometric scaling) is not common in clinical practice but decreases the variability in drug response between giant/large and small/toy breed dogs. See Conversion Tables: Body Weight (kg) to Body Surface Area (m 2 ).
- 4. For all dosages, the low end of the dose range is generally appropriate for IV administration, whereas the mid-upper range is most appropriate for IM or SC administration. Higher dosages will provide more profound sedation and analgesia.
- 5. When SC administration is used, the speed of sedation is slower, and the level of sedation is lighter and inconsistent. For more predictable sedation, IM or IV administration is recommended.
- 6. The effects of dexmedetomidine can be reversed with atipamezole. It is most often dosed by volume at ½ or the same volume of dexmedetomidine that was administered and given IM. See Atipamezole.
- Store the injection at room temperature (ie, 15°C-30°C [59°F-86°F]); do not freeze. Discard unused product 90 days after first piercing the vial.
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Overview
Dexmedetomidine is a potent, highly specific alpha-2 adrenergic agonist used primarily as a sedative, analgesic, and preanesthetic in veterinary medicine. It is the dextrorotatory enantiomer of medetomidine, making it approximately twice as potent as the racemic mixture.
Key Clinical Features:
- Biphasic Cardiovascular Response: Initial peripheral vasoconstriction leads to transient hypertension and a pronounced reflex bradycardia. This is followed by a central sympatholytic effect causing normotension or mild hypotension, while bradycardia persists.
- Analgesia: Provides excellent visceral and somatic analgesia, often synergistic with opioids (e.g., "kitty magic" or "doggie magic" protocols).
- Reversibility: Effects can be rapidly and completely reversed using the specific alpha-2 antagonist atipamezole.
- Dosing: In dogs, dosing is uniquely based on body surface area (BSA) rather than strictly by weight, as smaller dogs require higher per-kg doses to achieve similar sedation levels.
Mechanism of action
Dexmedetomidine acts as a highly selective agonist at pre-synaptic alpha-2 adrenergic receptors in the central and peripheral nervous systems.
- CNS Effects: Activation of alpha-2 receptors in the locus coeruleus → decreased norepinephrine release → profound sedation, anxiolysis, and analgesia.
- Cardiovascular Effects: Activation of peripheral post-synaptic alpha-2B receptors in vascular smooth muscle → intense vasoconstriction → increased systemic vascular resistance (SVR) → reflex bradycardia mediated by baroreceptors. Central alpha-2A activation subsequently decreases sympathetic outflow.
- Other Effects: Decreases GI secretions, alters intestinal motility, induces diuresis (via inhibition of ADH), and causes mild muscle relaxation.
Safety & warnings
Contraindications
- Cardiovascular disease
- Respiratory disorders
- Liver or kidney diseases
- Shock or severe debilitation
- Stress due to extreme heat, cold, or fatigue
- Puppies < 16 weeks (US label) or < 6 months (UK label)
- Kittens < 12 weeks (US label) or < 5 months (UK label)
- Hypersensitivity to the active substance
Adverse effects
- Bradycardia (profound)
- Occasional AV blocks
- Decreased respiration / Apnea
- Hypothermia
- Urination
- Vomiting
- Hyperglycemia
- Pain on injection (IM)
- Prolonged sedation
- Paradoxical excitation
- Hypersensitivity
- Pulmonary edema
- Death from circulatory failure (rare)
- Muscle tremors
- Transient hypertension
- Reduced tear production
Precautions
Cardiovascular Warning: Due to pronounced cardiovascular effects (bradycardia, vasoconstriction), only clinically healthy dogs and cats should be treated.
- Seizure Disorders: Use with caution in animals with or prone to developing seizures; may lower the seizure threshold.
- Ocular Care: Blinking may be impaired and tear production reduced; eye lubricants should be applied during sedation.
- Pregnancy/Nursing: Not recommended for use in pregnant or breeding animals unless benefits clearly outweigh risks (FDA Category C). Safe use during nursing is not established.
Drug interactions
Effects may be additive; dosage reduction of one or both agents may be required. General anesthetic requirements may be reduced between 30-60%.
Can significantly increase arterial blood pressure and heart rate; use together is not recommended in dogs due to increased cardiac workload.
Possesses alpha agonist effects; do not use to treat cardiac effects caused by dexmedetomidine.
May reverse the effects, but atipamezole is preferred for clinical use.
Monitoring
- Level of sedation and analgesia
- Heart rate and rhythm
- Blood pressure
- Respiration rate and pulse oximetry
- Body temperature (monitor for hypothermia)
Pharmacokinetics
Half-life
Absorption
Dogs: IM bioavailability 60%, peak plasma levels in ~35 minutes. Cats: IM peak plasma levels in ~15 minutes. OTM (buccal) administration provides similar clinical effects to IM.
Distribution
Dogs: Vd is 0.9 L/kg. Cats: Vd is 2.2 L/kg.
Metabolism
Primarily metabolized in the liver via glucuronidation and N-methylation. No active metabolites.
Elimination
Eliminated primarily in the urine and to a lesser extent in the feces.
Overdose
Single doses of up to 5X (IV) and 10X (IM) were tolerated in dogs, but adverse effects (heart block, PVCs, tachycardia, profound sedation) can occur.
Important: Treatment of dexmedetomidine-induced bradycardia with anticholinergic agents (atropine or glycopyrrolate) is usually not recommended due to the risk of severe hypertension and arrhythmias.
Atipamezole is the safest and most effective choice to reverse any dexmedetomidine-induced effects or overdose.
Available products
Formulations
- Injection: 0.5 mg/mL (500 mcg/mL)
- Concentrated Solution for Injection: 100 mcg/mL
Veterinary
- Dexmedetomidine HCl 0.5 mg/mL (500 micrograms/mL) in 10 mL multidose vials (Dexdomitor)
Human-labeled
- Dexmedetomidine HCl Concentrated Solution for Injection: 100 micrograms/mL in 2 mL vials (Precedex)
Regulatory status
No regulatory data for: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Storage & stability
Store the injection at room temperature (15-30°C); do not freeze. Can be mixed in the same syringe with butorphanol, ketamine, buprenorphine, hydromorphone, or morphine with no pharmacological risk.
Client information
- Professional Use Only: This drug should be administered and monitored by veterinary professionals only.
- Post-Sedation Care: Keep your pet in a quiet, warm, and comfortable environment after they return home. They may remain slightly groggy.
- Risks: Be aware of potential adverse effects, particularly if your dog is older or has pre-existing heart, liver, or kidney conditions.
- Diet: Follow your veterinarian's instructions regarding fasting before the procedure and when to resume feeding afterward.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.